The World Health Organisation (WHO) has published the third edition of the Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, providing the most comprehensive global reference to date for interpreting genomic mutations associated with drug-resistant TB.
The updated catalogue strengthens the evidence base for molecular and sequencing-based drug resistance testing for the disease, supporting more consistent interpretation and use of genomic data across laboratories, surveillance programmes, diagnostic developers and researchers worldwide.
It has been updated to:
include data from more than 71 000 clinical Mycobacterium TB isolates from more than 75 countries – representing 37% and 12% increases in volume and coverage over the second edition that was published in 2023;
expand evidence for newer and repurposed anti-TB medicines, including pretomanid and cycloserine;
incorporate updated bioinformatic and statistical methods to improve mutation classification;
introduce an enhanced interpretation framework in which the Graded Mutation List is applied, with additional grading rules and other interpretation criteria to support appropriate interpretation of drug resistance;
provide strengthened practical guidance and new FAQs to support users in understanding, applying and implementing the catalogue; and
strengthen support for sequencing-based drug susceptibility testing, the development and evaluation of molecular diagnostics, and global TB drug resistance surveillance.
It builds on the first WHO mutation catalogue, published in 2021, and the second edition released in 2023, reflecting continued international collaboration among national TB programmes, supranational reference laboratories, academic institutions and technical partners to improve the evidence base for genomic drug-resistance testing.
See more from MedicalBrief archives:
New antibiotic-resistant genes identified in TB in 23-country analysis
WHO adds to current drug-resistant TB treatment guidelines
